We are live on ! Find out more

BioHarvest Sciences

BHST

Market cap $36.7M

1.62 USD

-0.04

2.41%

At close Updated Oct 12, 4:00 PM EDT

1 day

-2.41%

5 days

10.96%

1 month

-10%

3 months

-41.52%

6 months

-62.15%

Year to date

-68.91%

1 year

-87.04%

5 years

-71.83%

10 years

-71.83%

About: BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.

Employees: 89

Consumer Staples Packaged Foods

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 26.3%

Neutral 68.4%

Negative 5.3%

Proactive Investors

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle. Tate & Lyle, a supplier of ingredient solutions for food and beverages, is looking to broaden its range of sweeteners as manufacturers seek ways to cut sugar and calories without losing taste and functionality, the companies said.

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution.

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

Proactive Investors

BioHarvest Sciences launches buyback of up to 5% of shares

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said Tuesday its board has authorized a share repurchase program covering up to 5% of its outstanding common shares. The company, which develops and manufactures proprietary plant-based compositions for customers, partners and its own portfolio, will structure the program as a normal course issuer bid, in line with Canadian practice.

BioHarvest Sciences launches buyback of up to 5% of shares

BioHarvest Sciences Announces Share Repurchase Program

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in accordance with Canadian practices as a normal course issuer bid (the "NCIB"). The Company's Board of Directors believes that the market price of the Common Shares may not fully reflect the underlying value of the Company's business and future growth prospects.

BioHarvest Sciences Announces Share Repurchase Program

BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product

Single-dose VINIA Daily Chews broaden demographics and usage occasions while demonstrating the commercial versatility of Botanical Synthesis Format expansion shows how BioHarvest can help CDMO partners move from plant-cell compositions to differentiated consumer products Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 15, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers and its own portfolio, today announced the launch of single-dose VINIA® Daily Chews. The new delivery format is designed to expand the addressable market for VINIA and to further demonstrate BioHarvest's progress toward leadership in industrial-scale Botanical Synthesis, the platform behind the Company's approach to consistent, full-spectrum plant compounds at scale.

BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product

BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026, in New York City, NY.

BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Proactive Investors

BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) plans to pursue a dual listing of its ordinary shares on the Tel Aviv Stock Exchange (TASE), with trading expected to begin on September 8, 2026. The company, which is listed on the Nasdaq Capital Market, expects the TASE listing to provide investors in Israel with access to its shares.

BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing

BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026.

BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Q2 Earnings Call Highlights

BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from $8.5 million a year earlier, while highlighting its first manufacturing and supply agreement within its contract development and manufacturing organization, or CDMO, business.

BioHarvest Sciences Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™